RNXTHealthcare · BiotechnologyThe 4 Wall Street analysts covering RenovoRx, Inc. hold a median 12-month price target of $5.5 — +318.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores RenovoRx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (81): Smaller than most of the companies we track.
Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RNXT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +318.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 June 2026 | Ascendiant Capital | Maintains | Buy | $14 → $14 |
| 9 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 8 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Feb 2026 | Ascendiant Capital | Maintains | Buy | — |
| 21 Nov 2025 | Ascendiant Capital | Maintains | Buy | — |
| 25 Aug 2025 | Ascendiant Capital | Maintains | Buy | — |
| 5 June 2025 | Ascendiant Capital | Maintains | Buy | — |
| 19 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Apr 2025 | Ascendiant Capital | Maintains | Buy | — |
| 4 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Mar 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 10 Dec 2024 | Ascendiant Capital | Maintains | Buy | — |
| 12 Sept 2024 | Ascendiant Capital | Maintains | Buy | — |
| 17 June 2024 | Ascendiant Capital | Initiates | Buy | — |
| 2 Feb 2024 | Alliance Global Partners | Initiates | Buy | — |
| 15 Nov 2023 | Maxim Group | Downgrade | Hold | — |
| 18 Aug 2023 | Roth MKM | Maintains | Buy | — |
| 1 Nov 2021 | Roth Capital | Initiates | Buy | — |
| 6 Oct 2021 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RNXT appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 7% of US stocks
Cheaper than 16% of US stocks
Cheaper than 76% of US stocks
Higher than 94% of US stocks
Higher than 89% of US stocks
Higher than 94% of US stocks
Higher than 8% of US stocks
Higher than 98% of US stocks
Higher than 11% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own RenovoRx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
RenovoRx announced it received written notification from Nasdaq confirming the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
Why it matters — This removes the risk of delisting from Nasdaq related to the minimum bid price requirement, supporting RenovoRx's continued listing status.
RenovoRx announced it received a Notice of Allowance for a new U.S. patent covering RenovoCath, an advanced dual-occlusion catheter for targeted therapeutic drug-delivery in cancer treatment. The company continues to strengthen its intellectual property portfolio, which now includes 20 issued or allowed patents and 13 pending patents supporting RenovoCath commercialization.
Why it matters — A watcher would care because the patent allowance strengthens RenovoRx's intellectual property position for RenovoCath as its commercial and clinical programs advance.
RenovoRx executives and physician speakers discussed locally advanced pancreatic cancer treatment, the company's Trans-Arterial Micro-Perfusion (TAMP) platform, and commercialization progress for its RenovoCath delivery device during a JonesTrading-hosted webinar. The company is targeting a 2027 readout for its TIGeR-PaC trial while RenovoCath expands to 21 centers.
Why it matters — RNXT watchers would care because the webinar highlights ongoing commercialization progress for RenovoCath and the anticipated 2027 TIGeR-PaC data readout, key milestones for the company.
RenovoRx reported record second-quarter revenue while expanding its commercial cancer-center network and advancing its clinical program for locally advanced pancreatic cancer.
Why it matters — The record revenue and progress in both commercial expansion and its pancreatic cancer clinical program signal operational growth for RNXT watchers.
RenovoRx reported a Q2 loss of $0.05 per share, which beat the Zacks Consensus Estimate of a loss of $0.08 per share and improved from a loss of $0.08 per share in the same quarter last year.
Why it matters — The smaller-than-expected loss signals potential cost management improvement or operational progress for RenovoRx.
The 4 Wall Street analysts covering RenovoRx, Inc. have a median 12-month price target of $5.5, with estimates ranging from $3 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering RenovoRx, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks RenovoRx, Inc. 37 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, RenovoRx, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (81 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +318.3% from the last close, and Ticker Nerd's factor model ranks RenovoRx, Inc. 37 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering RenovoRx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNXT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $14 over the next 12 months.
RenovoRx, Inc. returned +47.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
RenovoRx Inc. is a biopharmaceutical company focused on the development of innovative cancer therapies.
The most recent item we track (GlobeNewsWire, 21 Aug 2026): "RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement". RenovoRx announced it received written notification from Nasdaq confirming the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
RenovoRx Inc. is a biopharmaceutical company focused on the development of innovative cancer therapies. Its primary mission is to improve the survival outcomes and quality of life for patients diagnosed with difficult-to-treat cancers. The company is particularly known for its proprietary Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver targeted chemotherapy directly to tumors, enhancing treatment efficacy while minimizing systemic exposure and associated toxicities. RenovoRx is pioneering breakthroughs in targeted intra-arterial chemotherapy, especially for pancreatic cancer, which is known for its low survival rates and limited treatment options. With its novel approach, RenovoRx aims to transform the therapeutic landscape within oncology. Positioned within the biotechnology sector, the company plays a significant role in advancing precision medicine, offering hope for improved patient outcomes through tailored therapeutic strategies. As a cutting-edge player in the sector, RenovoRx continues to explore regulatory pathways and conducts clinical trials to validate its approaches and seek approvals for broader clinical use.
CEO Mr. Shaun R. Bagai · 17 employees · United States · https://renovorx.com